Ulcerative Colitis
Also known as: UC
Ulcerative colitis is a chronic inflammatory bowel disease that causes long-lasting inflammation and ulcers in the innermost lining of the large intestine and rectum. Symptoms typically develop over time and can include bloody diarrhea, abdominal pain, and an urgent need to have bowel movements. While there is no cure, treatment can significantly reduce symptoms and even bring long-term remission.
Last updated November 10, 2026
Understanding Ulcerative Colitis
Ulcerative colitis is a lifelong inflammatory disease of the large bowel in which the immune system attacks the inner lining of the colon, always starting at the rectum and extending upward in a continuous stretch. It affects roughly 1 million Americans and is slightly more common than Crohn's disease; new diagnoses run at about 10 to 20 per 100,000 people a year, most often between 15 and 30 with a smaller second peak after 50, and men and women equally. About a third of people have disease confined to the rectum (proctitis), a third have left-sided colitis and a third have extensive colitis beyond the splenic flexure, and extent can grow over time. Historically a Western disease, it is now rising fastest in Asia and South America as diets and environments change. Around 15 percent will have at least one severe flare needing hospital admission, and about 10 to 15 percent need colectomy within 10 years in modern series, down from 20 to 30 percent in the pre-biologic era.
The colon lining is protected by a mucus layer and a single sheet of epithelial cells; in ulcerative colitis that barrier is thinner, the bacterial community beneath it is altered (fewer butyrate-producing species such as Faecalibacterium prausnitzii), and immune cells pour into the mucosa releasing tumor necrosis factor, interleukin-13, interleukin-23 and the integrin signals that pull more white cells in from the blood. More than 200 genetic risk variants are known, but genes explain only part of it: smoking, oddly, is protective and quitting is a common trigger, appendectomy in youth lowers risk, and NSAIDs and gut infections can set off flares. The course is relapsing and remitting; in any given year roughly half of patients are in remission, 30 percent have mild activity and the rest moderate to severe, and about 10 percent have continuous symptoms. Inflammation that never fully heals drives the two long-term risks: colorectal cancer, which rises after eight years of extensive disease, and loss of colon function. Extraintestinal problems, joint pain, eye inflammation, skin lesions and primary sclerosing cholangitis, affect about a quarter of patients.
Treatment follows the American College of Gastroenterology 2019 guideline and the American Gastroenterological Association's 2020 guideline for moderate to severe disease, and the goal has shifted from feeling better to healing the lining on colonoscopy (the STRIDE-II treat-to-target framework). Mild to moderate disease responds to mesalamine, at least 2 g a day by mouth plus suppositories or enemas for rectal disease, since the combination outperforms either alone; budesonide MMX is the next step. Moderate to severe disease is treated with an advanced therapy: anti-TNF antibodies (infliximab, adalimumab, golimumab), vedolizumab, ustekinumab, the IL-23 blockers mirikizumab, risankizumab and guselkumab, oral JAK inhibitors (tofacitinib, upadacitinib) or S1P modulators (ozanimod, etrasimod). In the only large head-to-head trial, VARSITY (769 patients), vedolizumab achieved clinical remission at one year in 31 percent versus 23 percent with adalimumab. Steroids are for flares only; needing more than one course a year means treatment should be stepped up. A severe flare, more than six bloody stools a day with fever, fast pulse or anemia, is a hospital emergency treated with intravenous steroids and, if there is no response by day three to five, rescue infliximab or cyclosporine, or surgery. Colonoscopy surveillance begins eight years after diagnosis.
Several natural products have real trial data as add-ons to standard therapy, and none replaces it. Curcumin is the strongest: in a 50-patient trial, 3 g a day added to mesalamine produced clinical remission at four weeks in 54 percent versus none on placebo, and 2 g a day for six months cut relapse from 21 to 5 percent in an 89-patient maintenance trial. The de Simone multi-strain probiotic (sold as VSL#3 and Visbiome) roughly doubled remission in two trials of about 150 patients each, and Escherichia coli Nissle 1917 matched mesalamine for maintenance in a 327-patient trial, though it is not sold in the US. Psyllium, aloe vera gel and Boswellia each have one small positive trial. Vitamin D deficiency is common and linked to flares, so a level is worth checking. What does not work: omega-3 fish oil, which failed to prevent relapse in Cochrane's review of six trials; elimination diets as sole therapy; and kombucha, colloidal silver or 'leaky gut' protocols. Fecal microbiota transplant induces remission in about a quarter of patients in trials but remains experimental outside research settings.
The most common mistake is stopping maintenance medication when you feel well. Mesalamine in particular feels optional once stools are normal, yet in a study of 99 patients in remission, those who took less than 80 percent of their prescribed dose were more than five times as likely to relapse within a year. Advanced therapies are worse to stop and restart, because antibodies against the drug can form and it may not work a second time. The second mistake is reaching for ibuprofen or naproxen for the joint pains that accompany the disease; NSAIDs are linked to a flare within weeks in about a fifth of users, and acetaminophen is the safer default. What to do instead: treat the medication like insulin rather than a painkiller; if cost, side effects or pill burden are the problem, say so, because once-daily formulations, patient-assistance programs and alternative drugs exist; and ask for a fecal calprotectin test to check inflammation objectively rather than relying on symptoms alone.
At a Glance
- Common symptoms
- Diarrhea, often with blood or pus, Abdominal pain and cramping, Rectal pain and bleeding
- Main treatments
- 5-aminosalicylates (mesalamine) for mild to moderate disease, Corticosteroids for acute flares, Immunomodulators such as azathioprine or 6-mercaptopurine
- Category
- Digestive · Affects approximately 600,000-900,000 people in the US
- See a doctor if
- Persistent diarrhea with blood
Symptoms
Causes
- Abnormal immune response attacking the colon lining
- Genetic predisposition with multiple genes involved
- Environmental triggers that are not fully understood
- Possible role of gut microbiome dysbiosis
Risk Factors
- Family history of inflammatory bowel disease
- Age between 15 and 30 years, with a second peak between 50 and 70
- White or Ashkenazi Jewish descent
- Previous NSAID use may trigger or worsen flares
Diagnosis
- Colonoscopy with biopsy showing characteristic mucosal inflammation
- Blood tests for anemia, inflammation markers, and nutritional deficiencies
- Stool tests to rule out infections and measure calprotectin
- CT or MRI enterography to assess disease extent
Treatment
- 5-aminosalicylates (mesalamine) for mild to moderate disease
- Corticosteroids for acute flares
- Immunomodulators such as azathioprine or 6-mercaptopurine
- Biologic therapies including anti-TNF agents, vedolizumab, or ustekinumab
- JAK inhibitors such as tofacitinib
- Colectomy for severe or medication-refractory disease
Natural remedies for ulcerative colitis: what the evidence says
Ranked by the strength of human evidence for ulcerative colitis specifically. These sit alongside medical care, not in place of it.
Curcumin
Moderate evidenceIn a 2015 Israeli multicenter trial, 50 people with mild to moderate UC not responding to mesalamine added 3 g of curcumin capsules or placebo for one month: clinical remission was 54 percent versus 0 percent and endoscopic improvement 38 versus 0 percent. In a 2006 Japanese trial, 89 patients in remission took 1 g twice daily or placebo with their mesalamine for six months; relapse was 4.7 versus 20.5 percent. Lower doses and plain turmeric powder have not shown the same effect, and a small trial of curcumin enemas was also positive for distal disease.
- Studied dose
- 2 to 3 g of standardized curcumin (95 percent curcuminoids) daily in divided doses with food, alongside mesalamine; formulations with piperine or phospholipid improve absorption.
- Cautions
- Can increase bleeding with anticoagulants, lower blood sugar with diabetes drugs and inhibit several liver enzymes; rare liver injury has been reported with high-absorption products. Can worsen gallbladder pain and reduce iron absorption, so take 2 hours apart from iron.
Probiotics (Multi-strain Lactobacillus Blend)
Moderate evidenceThe de Simone formulation (eight strains of Lactobacillus, Bifidobacterium and Streptococcus thermophilus) at 3.6 trillion CFU daily induced remission in 42.9 percent versus 15.7 percent on placebo in a 147-patient Indian trial over 12 weeks, and halved disease activity scores in a 144-patient Italian trial. Single-strain lactobacillus products, Saccharomyces boulardii and kefir have not shown benefit in UC. It is an add-on for mild to moderate disease and has no role in acute severe colitis.
- Studied dose
- VSL#3 or Visbiome, 1 to 2 sachets (450 billion to 3.6 trillion CFU) daily with food for at least 8 to 12 weeks.
- Cautions
- Bloating in the first weeks is common. Avoid during hospital admission, with central lines or severe immunosuppression, where bacteremia has been reported. It is expensive, so check the strain list and CFU count rather than buying a generic blend.
Vitamin D
Preliminary evidenceAbout 40 percent of people with UC are vitamin D deficient, and low levels are associated with higher disease activity, more hospital admissions and higher colorectal cancer risk in cohort studies. Supplementation trials are small: in a 2017 pilot of 60 UC patients, 4,000 IU daily for 90 days lowered disease activity scores more than 2,000 IU, and other small trials show lower inflammatory markers with repletion. Steroids and inflammation both lower vitamin D and raise bone loss, so checking a level is standard care.
- Studied dose
- Test first, then 1,000 to 2,000 IU daily for maintenance, or 2,000 to 4,000 IU for deficiency with a recheck at 3 months.
- Cautions
- Avoid high doses without monitoring calcium. Cholestyramine, orlistat and active inflammation reduce absorption.
Psyllium
Preliminary evidenceIn a 102-patient Spanish trial, 10 g of psyllium (Plantago ovata) twice daily, mesalamine 500 mg three times daily or both were compared over 12 months of maintenance; relapse rates were 40, 35 and 30 percent respectively, so psyllium performed close to mesalamine, though the trial was open-label and too small to prove equivalence. The benefit is thought to come from fermentation to butyrate, the main fuel of colon cells.
- Studied dose
- 10 g psyllium husk twice daily in a full glass of water, starting at 5 g and increasing over a week.
- Cautions
- Not during a flare with severe cramping, or with any stricture or obstruction. Take 2 hours apart from medications because it reduces their absorption, and drink enough fluid.
Aloe Vera
Preliminary evidenceIn a 44-patient UK double-blind trial, 100 mL of oral aloe vera gel twice daily for four weeks produced clinical remission in 30 percent versus 7 percent on placebo and improvement in 47 versus 14 percent, with a trend toward better histology. It is a single small trial that has not been repeated.
- Studied dose
- 100 mL of decolorized inner-leaf aloe vera gel (not whole-leaf or latex) twice daily for 4 weeks.
- Cautions
- Whole-leaf and latex products contain anthraquinones that cause diarrhea and potassium loss and are classed as possible carcinogens; use only purified inner-leaf gel. May lower blood sugar and add to diarrhea in some people.
Boswellia
Preliminary evidenceIn a 1997 Indian trial, 34 patients with UC received Boswellia serrata gum resin 350 mg three times daily or sulfasalazine for six weeks; 82 versus 75 percent went into remission, but the trial was small, unblinded and has not been reproduced in a modern design. A later 30-patient trial in chronic colitis reported similar results. Laboratory work shows boswellic acids block 5-lipoxygenase, an inflammatory enzyme.
- Studied dose
- 300 to 400 mg of standardized extract three times daily with food.
- Cautions
- Heartburn, nausea and loose stools; may add to anticoagulant and NSAID effects, and inhibits liver enzymes that metabolize some immunosuppressants, so check with your gastroenterologist if you take tacrolimus or similar drugs.
What matters day to day
- Take maintenance medication every day even in remission: patients taking under 80 percent of prescribed mesalamine were more than five times as likely to relapse within a year in a prospective study.
- Use acetaminophen, not ibuprofen or naproxen, for pain: NSAIDs trigger a flare within days to weeks in roughly 20 percent of people with inflammatory bowel disease.
- Eat a Mediterranean-style pattern and go easy on red and processed meat and alcohol: in a 191-patient cohort, high meat intake roughly tripled the odds of relapse and heavy alcohol intake more than doubled it, while fruit, vegetables and fiber were not harmful between flares.
- Address stress and sleep: gut-directed hypnotherapy kept 68 percent of patients in remission at one year versus 40 percent with usual care in a 54-patient trial, and sleeping under six hours is linked to higher flare rates.
- Keep vaccinations current before starting advanced therapy, including flu, pneumococcal, hepatitis B and the recombinant shingles vaccine, which matters most before JAK inhibitors, and have a yearly skin check if you take thiopurines or anti-TNF drugs.
- Ask for routine labs at least yearly, including ferritin and iron saturation, vitamin D, CRP and a fecal calprotectin: iron deficiency affects a third of UC patients and calprotectin predicts a flare months before symptoms do.
Prevention
- No known prevention for developing ulcerative colitis
- Medication adherence to maintain remission and prevent flares
- Regular colonoscopic surveillance for colorectal cancer
When to See a Doctor
- Persistent diarrhea with blood
- Abdominal pain that is ongoing or severe
- Unexplained fever lasting more than a day or two
- Inability to maintain adequate nutrition or hydration
Frequently Asked Questions
References
- Rubin DT, Ananthakrishnan AN, Siegel CA, et al.. ACG clinical guideline: ulcerative colitis in adults. American Journal of Gastroenterology (2019)
- Feuerstein JD, Isaacs KL, Schneider Y, et al.. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology (2020)
- Sands BE, Peyrin-Biroulet L, Loftus EV, et al.. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis (VARSITY). New England Journal of Medicine (2019)
- Lang A, Salomon N, Wu JC, et al.. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clinical Gastroenterology and Hepatology (2015)
- Hanai H, Iida T, Takeuchi K, et al.. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clinical Gastroenterology and Hepatology (2006)
- Sood A, Midha V, Makharia GK, et al.. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology (2009)
- Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine (2003)
- Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, et al.. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. American Journal of Gastroenterology (1999)
- Langmead L, Feakins RM, Goldthorpe S, et al.. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Alimentary Pharmacology and Therapeutics (2004)
- National Institute of Diabetes and Digestive and Kidney Diseases. Ulcerative Colitis (2024)View source
Related Conditions
Evidence-graded guides
Lab tests that relate to ulcerative colitis
Related from the Supplement Library
Omega-3 (EPA/DHA)
StrongFatty Acid · Cardiovascular health (TG reduction, anti-arrhythmic)
Probiotics (Lactobacillus)
StrongProbiotic · Gut microbiome balance and diversity
Turmeric
StrongHerb · Reduces systemic inflammation (NF-κB pathway)
L-Glutamine
ModerateAmino Acid · Gut lining repair and intestinal integrity
Vitamin D
StrongVitamin · Bone health and calcium absorption
These supplements have been studied in relation to Ulcerative Colitis. Always consult your healthcare provider before starting any supplement, especially if you take medications.
Have questions about Ulcerative Colitis?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.